In this section:

04 August 2017

Fumaric Acid Treatment Draft-Approved for Psoriasis in the UK

The National Institute for Health and Care Excellence (NICE) has today published its Final Appraisal Determination on the use of dimethyl fumarate (Skilarence) for severe psoriasis in England and Wales.

Dimethyl fumarate (Skilarence) is recommended to treat severe psoriasis, where people have not had adequate results from conventional systemic treatments, or cannot take them.

Some people with psoriasis may be aware of a similar treatment, known as Fumaderm or Fumaric Acid Esters. This is a German treatment that is not licensed in the UK, but has sometimes been prescribed on a case-by-case basis. Dimethyl fumarate (Skilarence) is licensed in the UK, and uses the main active ingredient from Fumaderm. This, along with today’s NICE recommendation, should make fumaric acid ester treatment more accessible to people with psoriasis in the UK.

We will be publishing more information on dimethyl fumarate (Skilarence) for psoriasis soon. In the meantime, please get in touch with us if you have any questions.

The Psoriasis Association is the UK's leading national charity and membership organisation for people affected by psoriasis – patients, families, carers and health professionals Read More >

Get in touch

The Psoriasis Association Dick Coles House 2 Queensbridge Northampton NN4 7BF

Email: mail@psoriasis-association.org.uk

Tel :
01604 251 620
Fax :
01604 251 621
Registered with Fundraising Regulator -

© The Psoriasis Association Registered Charity: 257414 Scotland: SC039886 Privacy PolicyCookies

Site by Spoken Image | glitterfish

We use cookies to help us provide you with a better service, but do not track anything that can be used to personally identify you.

If you prefer us not to set these cookies, please visit our Cookie Settings page or continue browsing our site to accept them.